

## Psychopathology (Ch.16) III

- Depression
  - Symptoms, Epidemiological factors
  - Stress-related factors
  - Monoamine Hypothesis
  - Other Brain Abnormalities
  - Treatments
  - Animal models
  - Bipolar disorder/mania
- NOTE: No lectures on anxiety disorders- you will not be tested on this

## Depression: What is it?

- Major **unipolar** depression is one of the most common mood disorder, characterized by:
  - Unhappy mood (more an absence of happiness than increased sadness), worthlessness, guilt, desperation
  - Loss of interest, motivation (anergia), and appetite, blunted ability to experience pleasure (anhedonia)- or at least pursue it
  - Difficulty in concentration, restless agitation
- An episode of depression may occur with no apparent cause (endogenous) or can be triggered by external events (reactive)
  - High co-morbidity of depression w/ many other medical conditions
- Major costs to individual and society
  - Dramatically increased risk of suicide (7-15% vs ~1% general population)
  - Impact on relatives/friends of the individual with depression
  - Lost productivity costs



## DSM Diagnostic criteria for Major Depressive Disorder

**≥5 symptoms during the same two week period that are a change from previous functioning; depressed mood and/or loss of interest/pleasure must be present**

---

### Depressed mood

Most of the day, nearly every day; may be subjective (e.g. feels sad, empty, hopeless) or observed by others (e.g. appears tearful); in children and adolescents, can be irritable mood

---

### Loss of interest/pleasure

Markedly diminished interest/pleasure in all (or almost all) activities most of the day, nearly every day; may be subjective or observed by others

---

### Weight loss or gain

Significant weight loss (without dieting) or gain (change of >5% body weight in a month), or decrease or increase in appetite nearly every day; in children, may be failure to gain weight as expected

---

### Insomnia or hypersomnia

Nearly every day

---

### Psychomotor agitation or retardation

Nearly every day and observable by others (not merely subjectively restless or slow)

---

### Fatigue

Or loss of energy, nearly every day

---

### Feeling worthless or excessive/inappropriate guilt

Nearly every day; guilt may be delusional; not merely self reproach or guilt about being sick

---

### Decreased concentration

Nearly every day; may be indecisiveness; may be subjective or observed by others

---

### Thoughts of death/suicide

Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without specific plan, or suicide attempt, or a specific plan for suicide

---

- Symptom clusters vary with individuals; there are depression subtypes associated with distinct causes and pathophysiologies.
- Over 200 combination of different symptoms can be diagnosed as “depression”


## Epidemiological Factors in Depression

- Unipolar depression typically alternates with normal emotional states, with an episode lasting up to 6-9 months.
  - Episodes can recur through life, often increasing in frequency and intensity
- **Prevalence:** In North America, > 10% of population may be afflicted at any one time
  - Considerable sex difference: women more likely to be diagnosed
  - In women, incidence often coincides with major hormonal changes (post partum, menopause)
  - Incidence of depression has increased over the last 50 years, and age of onset has decreased (currently ~ 27 years old)
  - **Genetic influences:** Some types of depression may have a genetic influence, whereas others less so

### Share of the population with depression, 2016

Prevalence of depressive disorders in a given population. This is measured as the age-standardized prevalence, which assumes a constant age structure to compare between countries and through time. Figures attempt to provide a true estimate (going beyond reported diagnosis) of depression prevalence based on medical, epidemiological data, surveys and meta-regression modelling.

Our World  
in Data




Source: IHME, Global Burden of Disease

CC BY


# Stress and Depression (I)

- Depression is viewed as a stress-related disorder
  - Can emerge during stressful life periods
- At least some forms of depression may be linked to alterations in HPA-axis and higher cortisol (CORT) levels
  - People with **Cushing's syndrome** have high levels of glucocorticoids and are prone to depression.
- Circulating CORT levels tend to be higher in depressed subjects vs other disorders or controls.
- A popular theory of depression is the **diathesis-stress model** (ie: an individual has some sort of predisposition for depression, and stress can trigger the syndrome)



## Stress and Depression (II)


- The **dexamethasone suppression test** can show excessive CORT release
- Dexamethasone, a synthetic glucocorticoid, can suppress CORT release in normal people, but not in depressed patients.



- Dexamethasone can “fool” the HPA axis into believing there are higher levels of CORT than normal – through negative feedback, levels drop in healthy controls
- In many depressed patients, negative feedback mechanisms are disrupted.

# The Monoamine Hypothesis of Depression

- Three major monoamine neurotransmitters are **5-HT**, **noradrenaline** and **dopamine**
- **1950-60s: Reserpine** (drug that reduces monoamine levels) induces depression
- First **monoamine oxidase inhibitors** (which block metabolism of monoamines and increase brain levels) alleviated depression
- First tricyclic antidepressant (**Imipramine**, which blocks monoamine reuptake) also found effective



- **1980s: Fluoxetine (aka-Prozac™)** a -selective serotonin reuptake inhibitor (SSRI) found to be effective at treating depression
- All of these findings support the **monoamine hypothesis**:
- **Depression is the result of abnormal reductions in brain monoamine (mostly 5-HT and noradrenaline) levels**

## Treatment Issues and Limitations of the Monoamine Hypothesis


- **1) Antidepressants increase monoamine levels quickly, yet there is a lag in the reduction of symptoms** (chronic treatment is required)
- **2) Not all depressed patients respond to drugs that increase monoamine levels**
  - There is a large placebo effect – antidepressants tend to improve symptoms vs placebo in the most severely depressed patients
  - SSRIs are not more effective than classic tricyclics that effect noradrenaline release as well (but have fewer side effects)
- **3) SSRIs associated with increased risk of suicide in children and adolescents** (but causal relationship unclear).
- **4) In animal models, depletion of 5-HT does not cause a depressive-phenotype**
  - Suggest that there is more to the disorder than merely a overall decrease in 5-HT levels in the brain



## Brain Changes With Depression

Functional imaging studies have revealed:

- Increased blood flow to amygdala and ventral parts of medial prefrontal cortex
  - Some aspects of depression may be caused by disrupted regulation of amygdala emotional processing by certain parts of PFC
- Alterations in brain activation can be ***normalized with antidepressant treatment***
- Reduced hippocampal volumes also observed
- Dysfunction of prefrontal cortex may be one of the underlying mechanisms that leads to aberrant negative appraisals of life events (everything seems a lot worse than it is, persistent rumination on negative events)



## Other Treatments for Depression


- ***Electroconvulsive shock therapy (ECT)***: one of the original treatments for depression
  - Method of action poorly understood, still used today in extreme cases.
- ***Transcranial magnetic stimulation (TMS)*** also alters cortical electrical activity.
- ***Deep Brain Stimulation (DBS)*** – electrode is surgically implanted in brain, very high frequency stimulation given continuously.
  - Thought to inactivate targeted brain region – DBS in ventromedial PFC or other subcortical areas has been shown to be effective at alleviating depression in **treatment resistant** patients
  - No controlled experiments have been done



## Other Treatments for Depression

- **Ketamine** (non-competitive NMDA antagonist): Sub-anesthetic doses induce rapid reduction in symptoms for ~70% of treatment-resistant patients (after psychosis dissipates).
  - Effects last 1-3 weeks
  - Nasal formulation recently approved for use
- Method of action not fully understood, but may be linked to increased cortical activity
- ***Cognitive/Behavioural Therapy*** – takes a longer time, but ***just as effective*** as antidepressant drugs – when used in combination with other treatments, even more effective.


FIGURE 1. Change in Depression Severity Over Time in Patients With Treatment-Resistant Major Depression Given a Single Infusion of Ketamine or Midazolam<sup>a</sup>



## Animal Models of Depression

- **Models**: certain experimental manipulations may cause some sort of “depressed” condition in laboratory animals

- Learned helplessness animal is exposed to a repetitive, inescapable stressful stimulus. After repeated exposure, **some more sensitive** animals will not escape when given opportunity.




- Those that do not escape tend to have cellular/neurochemical alterations in the brain, (eg: decrease in 5-HT function).
- Acute antidepressant treatment can reduce behavioral despair

# Bipolar Disorder (Mania/Depression)



- **Bipolar disorder** is characterized by periods of depression alternating with expansive mood, or mania.
- The rate of cycling varies; rapid cycling consists of four or more cycles in one year.
  - Some may cycle several times in one day.
- Neural basis not fully understood but appears to involve abnormalities in the hippocampus, amygdala



- **Lithium** is a mood-stabilizing drug used to treat bipolar disorder that has widespread actions in the brain.
- Modulates 5-HT AND dopamine transmission
- Interacts with the circadian clock
- Lithium may enhance Brain Derived Neurotrophic Factor (BDNF) activity that may reduce cell death associated with bipolar disorder.